VRVladimir Rusinov

Vladimir Rusinov

*This is an algorithmically generated author record based on publicly available information.

Vladimir Rusinov has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 January 2015
      • Vol. 78  (2) , 34-8

    [Experimental comparative pharmacokinetics of levofloxacin, triazavirin, and related conjugate].

    by I V Blazhennikova, A F Kurliakova, V N Bykov, D S Geĭbo, A S Nikiforov, A V Stepanov, V N Charushin, O N Chupakhin, S K Kotovskaia, V L Rusinov

    A comparative study of the pharmacokinetics of levofloxacin and triazavirine as well as 2-methylthio-6-nitro-1,2,4-triazolo[5,1-ñ]-1,2,4-triazine-7(4Í)-ide (3S)-(-)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-7H-pyrido[1,2,3-d,e]-1,4-benzoxazine-6-carboxylic acid (conjugate 2) obtained by conjugation of triazavirine and levofloxacin, representing a new class of pharmacological agents, was carried out in experiments on rats. It is established that conjugate 2 in comparison to individual levofloxacin and triazavirine has a higher relative bioavailability and lower rate of elimination, which can lead to improved effectiveness of therapy at reduced dose and frequency of drug administration.


    • 1 January 2015
      • Vol. 60, 8-11

    [Investigation of Prophylactic Efficacy of Triazavirin Against Experimental Forest- Spring Encephalitis on Albino Mice].

    by S Ya Loginova, S V Borisevich, V L Rusinov, U N Ulomsky, V N Charushin, N Chupakhin, P V Sorokin

    Prophylactic efficacy of Triazavirin against experimental Forest-Spring encephalitis was studied on albino mice. vs. the active drug Ribavirin. A significant increase of the animal lifespan in the test groups (from 4 to 5 days) and a statistically (p < or = 0.05) valid decrease of the virus accumulation level in the target organ (the brain) were observed.


    • 13 March 2013
      • Vol. 57  (6) , 9-12

    [A new antiviral drug Triazavirin: results of phase II clinical trial].

    by O I Kiselev, E G Deeva, T I Mel'Nikova, K N Kozeletskaia, A S Kiselev, V L Rusinov, V N Charushin, O N Chupakhin

    The results of the clinical trial testing the efficacy of a new anti-influenza drug Triazavirin are presented in this work. The data of the trial were gathered during the 2010 influenza season. The treatment with oral Triazavirin significantly reduced the duration of the main clinical symptoms of influenza (intoxication, fever, respiratory symptoms), decreased the incidence of the influenza-related complications and the use of symptomatic drugs. The re-isolation rate of the influenza A and B viruses was significantly lower in the patients who were using Triazavirin. The analysis of the clinical data showed that the optimal prescribed dosage was 250 mg 3 times a day.


    • 1 January 2013
      • Vol. 76  (2) , 13-6

    [The antiaggregant action of 2-morpholino-5-(thienyl-2)-6-H-1,3,4-thiadiazine in in vitro and ex vivo experiments].

    by Iu S Logvinova, V A Makarov, O N Chupakhin, L P Sidorova, N M Perova, V L Rusinov

    The influence of 2-morpholino-5-(thienyl-2)-6-H-1,3,4-thiadiazine (H-29) on the platelet aggregation has been studied in experiments on donor plasma in vitro. It is established that H-29 causes a decrease in the platelet interaction induced by ADP and arachidonic acid. The influence of H-29 on platelet aggregation was also studied in ex vivo experiments with intravenous and oral administration, and some parameters of plasmatic hemostasis were evaluated.

  • Synthesis and antiviral activity of 1,2,4-triazine derivatives

    by V. L. Rusinov, I. N. Egorov, O. N. Chupakhin, E. F. Belanov, N. I. Bormotov, O. A. Serova


  • Open Access

    Efficient Synthesis of 2,2\'-Dicarbazole-1,1\'-Biphenyl - Prospective Host Material for PHOLEDs

    by Grigory Zyryanov, Oleg Chupakhin, Vladimir Rusinov, Dmitry Kopchuk, Igor Kovalev

    2,2\'-Dicarbazole-1,1\'-diphenyl (2,2\'-CBP) is a prospective host material for phosphorescent light emmiting diodes (PHOLED)s. The synthesis of 2,2\'-CBP is limited by the availability of starting materials. We wish to report an efficient protocol for the synthesis of 2,2\'-CBP with overal yield about 90% starting from o-nitrobenzoic acid. Thus, Pd catalized homocoupling of o-nitrobenzoic acid affords 2,2\'-dinitro-1,1\'-diphenyl (2,2\'-DNDP) in 95% yield. Pd catalized reduction of 2,2\'-DNDP and the following double arylation of 2,2\'-diaminodiphenyl with 2,2\'-dibromo-1,1\'-diphenyl (which can be obtained from 2,2\'-diamino-1,1\'-diphenyl in 70-76% yield) affords the final product in 95% yield with overal yield after 3 steps of 90 %.

    • 1 January 2011
      • Vol. 56, 10-2

    [Therapeutic efficacy of Triazavirin, a novel Russian chemotherapeutic, against influenza virus A (H5N1)].

    by S Ia Loginova, S V Borisevich, V A Maksimov, V P Bondarev, S K Kotovskaia, V L Rusinov, V N Charushin, O N Chupakhin

    Therapeutic activity of Triazavirin against experimental influenza A was studied on albino mice intranazally infected with influenza virus A/Chicken/Kurgan/Russia/02/05 (H5N1) vs. reference drugs (Oseltamivir, Remantadin and Arbidol). The study showed that in a therapeutic dose of 1 mg/kg Triazavirin was efficient in protection of the animals from death. Its protective therapeutic efficacy (36.7+/-1.7%) was close to that of Oseltamivir (50.0+/-0.0%), comparable with that of Remantadin (38.3+/-1.7%) and higher than that of Arbidol (11.7+/-1.7%). During the whole observation period (up to the terminal phase) Triazavirin inhibited the influenza virus A accumulation in the lungs of the infected albino mice by more than 3 lg.


    • 1 August 2010
      • Vol. 73  (8) , 21-5

    [Influence of new 1,3,4-thiadiazines on platelet aggregation in vitro and ex vivo].

    by O S Logvinova, T M Vasil'Eva, V A Makarov, O N Chupakhin, L P Sidorova, N M Perova, V L Rusinov

    The influence of new original 1,3,4-thiadiazines on the human platelet aggregation in vitro was studied. All substances inhibited the platelet aggregation induced by both ADP and arachidonic acid. 1,3,4-Thiadiazines L-19, H-30 and L-37 were the most effective inhibitors. Effect of the intravenous injection of L-19 in various doses on platelet aggregation and some parameters of plasmatic hemostasis were studied ex vivo.


    • 1 January 2010
      • Vol. 55, 25-8

    [Triazavirin prophylactic efficacy against influenza virus A (H5N1)].

    by S Ia Loginova, S V Borisevich, V A Maksimov, V P Bondarev, S K Kotovskaia, V L Rusinov, V N Charushin, O N Chupakhin

    The experimental study of the prophylactic efficacy of Triazaverin against the experimental form of the influenza virus A (H5N1) on albino mice intranasally infected with the influenza virus A/Chicken/Kurgan/Russia/02/05 vs. the reference drugs Tamiflu, Remantadin and Arbidol showed that in doses of 1 to 100 mg/kg it was efficient in the animal protection from death. The drug was also efficient in the urgent prophylaxis. Triazaverin effectively inhibited the influenza A virus multiplication in the lungs of the albino mice.


  • Synthesis and antiviral activity of nucleoside analogs based on 1,2,4-triazolo[3,2-c][1,2,4]triazin-7-ones

    by V. L. Rusinov, O. N. Chupakhin, S. L. Deev, T. S. Shestakova, E. N. Ulomskii, L. I. Rusinova, O. I. Kiselev, E. G. Deeva